Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 69 out of 100. How common it is

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background This is a progress report of the Alzheimer's Disease Neuroimaging Initiative (ADNI) positron emission tomography (PET) Core. Methods The Core has supervised the acquisition, quality control, and analysis of longitudinal [(18)F]fluorodeoxyglucose PET (FDG-PET) data in approximately half of the ADNI cohort. In an "add on" study, approximately 100 subjects also underwent scanning with [(11)C] Pittsburgh compound B PET for amyloid imaging. The Core developed quality control procedures and standardized image acquisition by developing an imaging protocol that has been widely adopted in academic and pharmaceutical industry studies. Data processing provides users with scans that have identical orientation and resolution characteristics despite acquisition on multiple scanner models. The Core labs have used many different approaches to characterize differences between subject groups (Alzheimer's disease, mild cognitive impairment, controls), to examine longitudinal change over time in glucose metabolism and amyloid deposition, and to assess the use of FDG-PET as a potential outcome measure in clinical trials. Results ADNI data indicate that FDG-PET increases statistical power over traditional cognitive measures, might aid subject selection, and could substantially reduce the sample size in a clinical trial. Pittsburgh compound B PET data showed expected group differences, and identified subjects with significant annual increases in amyloid load across the subject groups. The next activities of the PET core in ADNI will entail developing standardized protocols for amyloid imaging using the [(18)F]-labeled amyloid imaging agent AV45, which can be delivered to virtually all ADNI sites. Conclusions ADNI has demonstrated the feasibility and utility of multicenter PET studies and is helping to clarify the role of biomarkers in the study of aging and dementia.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 100 participants. It is a research-methods report and does not test any treatment, cure or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Jagust, W. J., Bandy, D., Chen, K., Foster, N. L., Landau, S. M., Mathis, C. A., et al. (2010). The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2010.03.003

Vancouver

Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2010. doi:10.1016/j.jalz.2010.03.003. PMID: 20451870.

BibTeX

@article{jagust2010-20451870,
  author  = {Jagust, W. J. and Bandy, D. and Chen, K. and Foster, N. L. and Landau, S. M. and Mathis, C. A. and Price, J. C. and Reiman, E. M. and others},
  title   = {{The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2010},
  doi     = {10.1016/j.jalz.2010.03.003},
  pmid    = {20451870},
  url     = {https://doi.org/10.1016/j.jalz.2010.03.003}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This 2010 progress report from the ADNI PET Core describes a standardised scanning protocol and image processing that make PET scans from different scanner models comparable; the authors say the protocol "has been widely adopted in academic and pharmaceutical industry studies." In ADNI data, FDG-PET "increases statistical power over traditional cognitive measures" and could reduce clinical-trial sample sizes, and in an add-on of about 100 people, amyloid PET showed expected differences between Alzheimer's, MCI and control groups and identified some people whose amyloid rose significantly each year; no figures are given in the record. It is a research-methods report and does not test any treatment, cure or prevention.

Study details

How this study scored 69/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 66 of the 96 points it could be judged on, which is 69 of 100. Total 69 of 100.66 of the 96 points we could judge = 69 of 100

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 66 of the 96 points we could judge it on, which is 69 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2010 — within 20 year(s) of the newest study here
Sample size 2 / 4 100 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 535 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 29.7 citations a year over 18 year(s) since 2010
Impact for its field and year 5 / 6 Cited 23.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 51 other studies in this library
Still being cited 3 / 4 Cited 65 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 2 / 3 University of Michigan: institution h-index 2,240 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 14 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 20451870)
Free to read 0 / 2 Behind a paywall — scores zero
Points 66 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 66 of the 96 points we could judge it on is 69 out of 100.
Total 69 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

51 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in How common it is from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on How common it is

See all studies in How common it is →